Physician profile
Annissa Rosser
NPI 1285290536
$10,097.45
in general payments reported to CMS, 2019-2025
25 companies · $3,805 in 2025
The $3,805 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $2,978 · 2024: $3,077 · 2025: $3,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,714 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,714.36 |
| Education | $145.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,441.88 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,311.54 | 2022-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,121.66 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,017.64 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $919.11 | 2023-2025 | Caplyta |
| Alkermes, INC. | $758.61 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $611.06 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Corium, LLC | $564.30 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $457.85 | 2024-2025 | Cobenfy |
| Indivior INC. | $345.33 | 2023-2025 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $318.98 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $292.61 | 2023-2025 | Auvelity |
| Lundbeck LLC | $187.99 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $140.70 | 2024-2025 | Fanapt, Hetlioz |
| Noven Pharmaceuticals, INC. | $124.74 | 2024 | Xelstrym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $121.17 | 2022 | |
| Janssen Scientific Affairs, LLC | $114.62 | 2025 | Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $74.53 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $46.74 | 2023-2025 | Trintellix |
| Tempus Ai, INC | $36.86 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.04 | 2025 | Jornay Pm |
| Luye Pharma (USA) LTD. | $19.34 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $17.69 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $17.30 | 2024 | Secuado |
| Scpharmaceuticals INC. | $15.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annissa Rosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.